Cravacitinib

Summary

Cravacitinib (CHEMBL4596392) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 51
• Chemistry: 422.4 Da · C20H22N8O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4596392
Name	Cravacitinib
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	138713709
Molecular formula	C20H22N8O3
Molecular weight	422.4
InChIKey	BZZKEPGENYLQSC-UHFFFAOYSA-N

SMILES: CNC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4

IUPAC name: 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-methylpyridazine-3-carboxamide

Also known as: Cravacitinib, DEUCRAVACITINIB

Parent form; salt/anhydrous children: CHEMBL4435170

Patent coverage: 13 distinct patent families (25 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 20 (80%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Tyrosine-protein kinase JAK2, Non-receptor tyrosine-protein kinase TYK2.

Bioactivity

ChEMBL activities: 12 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TYK2	8.29	EC50	5.13	nM	CHEMBL_ACT_28362629
TYK2	8.26	IC50	5.5	nM	CHEMBL_ACT_28943294
TYK2	8.25	IC50	5.6	nM	CHEMBL_ACT_28943240
TYK2	8.24	IC50	5.7	nM	CHEMBL_ACT_28943249
TYK2	8.19	EC50	6.53	nM	CHEMBL_ACT_28362635
JAK2	6.08	IC50	840	nM	CHEMBL_ACT_28943288
TYK2	5.68	IC50	2100	nM	CHEMBL_ACT_28943231
JAK2	5.66	IC50	2200	nM	CHEMBL_ACT_28943234
JAK2	5.64	IC50	2300	nM	CHEMBL_ACT_28943228
JAK2	5.64	IC50	2300	nM	CHEMBL_ACT_28943252
TYK2	5.54	IC50	2900	nM	CHEMBL_ACT_28943291
JAK2	5.52	IC50	3000	nM	CHEMBL_ACT_28943243

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 51.

Phase distribution

Phase	Trials
PHASE3	12
PHASE4	11
PHASE2	11
Not specified	11
PHASE1	3
EARLY_PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05858645	PHASE4	RECRUITING	Correction of Psoriatic T Cell Signatures by Deucravacitinib
NCT07013838	PHASE4	NOT_YET_RECRUITING	The Efficacy and Safety of Deucravacitinib in Takayasu’s Arteritis
NCT07280702	PHASE4	NOT_YET_RECRUITING	Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
NCT07352566	PHASE4	NOT_YET_RECRUITING	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT05478499	PHASE4	COMPLETED	Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
NCT05701995	PHASE4	COMPLETED	A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
NCT05710185	PHASE4	TERMINATED	Deucravacitinib for the Treatment of Palmoplantar Pustulosis
NCT06042920	PHASE4	TERMINATED	A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
NCT06329258	PHASE4	COMPLETED	Combination of Sotyktu and Enstilar for Plaque Psoriasis
NCT06333860	PHASE4	COMPLETED	A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
NCT06476834	PHASE4	COMPLETED	A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants
NCT04772079	PHASE3	RECRUITING	A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
NCT04908189	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
NCT04908202	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT05617677	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05620407	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05946941	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren’s Syndrome
NCT06143878	PHASE3	ACTIVE_NOT_RECRUITING	A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06220604	PHASE3	ACTIVE_NOT_RECRUITING	A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06869551	PHASE3	RECRUITING	A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06979453	PHASE3	RECRUITING	A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT07116967	PHASE3	RECRUITING	Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT06281106	PHASE2/PHASE3	TERMINATED	TYK2 Inhibition in Paradoxical Psoriasis
NCT06973291	PHASE3	COMPLETED	A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
NCT04857034	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
NCT06136403	PHASE2	RECRUITING	A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
NCT06327321	PHASE2	ACTIVE_NOT_RECRUITING	Vitiligo Treatment by Targeting TYK2 Mediated Responses
NCT06444399	PHASE2	RECRUITING	Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
NCT07508488	PHASE2	RECRUITING	Deucravacitinib in the Treatment of Cicatricial Alopecias
NCT04877990	PHASE2	COMPLETED	A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn’s Disease or Ulcerative Colitis
NCT05556265	PHASE2	TERMINATED	A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
NCT05997277	PHASE2	TERMINATED	Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
NCT06091956	PHASE2	COMPLETED	A Study of Deucravacitinib to Treat LPP and FFA
NCT06532136	PHASE2	WITHDRAWN	Deucravacitinib Rosacea
NCT06725264	PHASE2	WITHDRAWN	Tyrosine Kinase 2 (TYK2) for GA and CS
NCT04949269	PHASE1	COMPLETED	A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants
NCT06566768	PHASE1	COMPLETED	Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants
NCT06851871	PHASE1	COMPLETED	A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults
NCT05124080	EARLY_PHASE1	COMPLETED	An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis
NCT05821374	EARLY_PHASE1	WITHDRAWN	Deucravacitinib in PG

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).